 12. Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes Endocrinol. 2022; 10(6):393-406. doi:10.1016/S2213-8587(22)00070- 5 13. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study.Obesity (Silver Spring). 2014;22(1):5-13. doi:10.1002/oby.20662 14. Pozzilli P, Norwood P, Jódar E, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024-1031. doi:10. 1111/dom.12937 Research Original Investigation Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes 1640 JAMA November 7, 2023 Volume 330, Number 17(Reprinted) jama.com © 2023 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by F. Hoffmann - La Roche LTD user on 10/02/2024